BACKGROUND: The possibility of an association of Graves' disease (GD) with subsequent cancers has been previously reported. METHODS: Our study used the Taiwanese National Health Insurance Research Database (NHIRD), which identified 5025 newly diagnosed GD patients from 1997 to 2010, and 20,100 frequency matched non-GD patients. The risk of developing cancer for GD patients was measured using the Cox proportional hazard model. RESULTS: The incidence of developing cancer in the GD cohort was 4.92 per 1000 person-years and was 1.37-fold higher than in the comparison cohort (p<0.001). Compared with patients aged 20-34 years, older age groups demonstrated a higher risk of developing cancer (35-49 years: hazard ratio (HR)=4.15; 50-64 years: HR=7.39;≥65 years: HR=13.4). After adjusting for sex, age, and comorbidities, the HR for developing breast cancer and thyroid cancer was 1.58- and 10.4-fold higher for patients with GD. Furthermore, the incidence rates (IRR) were the highest in the first three years: 2.06 [confidence interval (CI)=1.87-2.27] and 15.6 [CI=13.9-17.5] in breast cancer and thyroid cancer with GD respectively. Specifically, a 16-fold hazard of developing thyroid cancer was present in the first three years in the GD cohort compared to the non-GD cohort [CI=7.95-32.1]. CONCLUSIONS: GD patients have a higher risk of cancer, particularly thyroid and breast cancer sequent within six and three years respectively. Strategies for preventing thyroid and breast cancer are proposed.
BACKGROUND: The possibility of an association of Graves' disease (GD) with subsequent cancers has been previously reported. METHODS: Our study used the Taiwanese National Health Insurance Research Database (NHIRD), which identified 5025 newly diagnosed GDpatients from 1997 to 2010, and 20,100 frequency matched non-GDpatients. The risk of developing cancer for GDpatients was measured using the Cox proportional hazard model. RESULTS: The incidence of developing cancer in the GD cohort was 4.92 per 1000 person-years and was 1.37-fold higher than in the comparison cohort (p<0.001). Compared with patients aged 20-34 years, older age groups demonstrated a higher risk of developing cancer (35-49 years: hazard ratio (HR)=4.15; 50-64 years: HR=7.39;≥65 years: HR=13.4). After adjusting for sex, age, and comorbidities, the HR for developing breast cancer and thyroid cancer was 1.58- and 10.4-fold higher for patients with GD. Furthermore, the incidence rates (IRR) were the highest in the first three years: 2.06 [confidence interval (CI)=1.87-2.27] and 15.6 [CI=13.9-17.5] in breast cancer and thyroid cancer with GD respectively. Specifically, a 16-fold hazard of developing thyroid cancer was present in the first three years in the GD cohort compared to the non-GD cohort [CI=7.95-32.1]. CONCLUSIONS:GDpatients have a higher risk of cancer, particularly thyroid and breast cancer sequent within six and three years respectively. Strategies for preventing thyroid and breast cancer are proposed.
Authors: J L Kraimps; M H Bouin-Pineau; M Mathonnet; L De Calan; J Ronceray; J Visset; R Marechaud; J Barbier Journal: Br J Surg Date: 2000-08 Impact factor: 6.939
Authors: A Belfiore; M R Garofalo; D Giuffrida; F Runello; S Filetti; A Fiumara; O Ippolito; R Vigneri Journal: J Clin Endocrinol Metab Date: 1990-04 Impact factor: 5.958
Authors: Orhan Turken; Yavuz NarIn; Sezai DemIrbas; M Emin Onde; Ozkan Sayan; E Gokhan KandemIr; Mustafa YaylacI; Ahmet Ozturk Journal: Breast Cancer Res Date: 2003-06-05 Impact factor: 6.466
Authors: P Premoli; M L Tanda; E Piantanida; G Veronesi; D Gallo; E Masiello; S Rosetti; C Cusini; F Boi; J Bulla; R Rodia; S Mariotti; V Capelli; M Rotondi; F Magri; L Chiovato; R Rocchi; M C Campopiano; R Elisei; P Vitti; F Barbato; T Pilli; M G Castagna; F Pacini; L Bartalena Journal: J Endocrinol Invest Date: 2019-07-20 Impact factor: 4.256
Authors: Cari M Kitahara; Dóra K Rmendiné Farkas; Jens Otto L Jørgensen; Deirdre Cronin-Fenton; Henrik Toft Sørensen Journal: J Clin Endocrinol Metab Date: 2018-06-01 Impact factor: 5.958
Authors: Frederik A Verburg; Martha Hoffmann; Ioannis Iakovou; Mark W Konijnenberg; Jasna Mihailovic; Pablo Minguez Gabina; Petra Petranović Ovčariček; Cristoph Reiners; Alexis Vrachimis; Slimane Zerdoud; Luca Giovanella; Markus Luster Journal: Eur J Nucl Med Mol Imaging Date: 2020-03 Impact factor: 9.236
Authors: Suzanne P MacFarland; Andrew J Bauer; N Scott Adzick; Lea F Surrey; Jessica Noyes; Ken Kazahaya; Sogol Mostoufi-Moab Journal: J Clin Endocrinol Metab Date: 2018-08-01 Impact factor: 5.958
Authors: Lars Folkestad; Frans Brandt; Thomas Brix; Marianne Vogsen; Lars Bastholt; Peter Grupe; Jeanette Krogh Petersen; Laszlo Hegedüs Journal: Eur Thyroid J Date: 2017-08-03